HALO
Halozyme Therapeutics margins
- Stocks
- Healthcare
- NASDAQ: HALO
- Margins
Recent Halozyme Therapeutics shows a gross margin of 82.4%, an operating margin of 35.9%, an EBITDA margin of 43.2%, and a net margin of 24.9%. EBITDA margin headed the decline across the available margins, falling by 24 percentage points.
HALO margin history
Over the last 3 years, Halozyme Therapeutics's margins averaged 82.05% gross, 46.46% operating, 56.65% EBITDA, and 36.85% net. For Halozyme Therapeutics, gross margin is above its three-year average, while operating, EBITDA, and net margins are below their three-year averages.
HALO margin expansion
Halozyme Therapeutics's gross margin contracted by 1.8 percentage points, operating margin by 22 percentage points, EBITDA margin by 24 percentage points, and net margin by 22.4 percentage points, led by EBITDA margin with a decline of 24 percentage points.
HALO Gross margin
Over the last 3 years, Halozyme Therapeutics's gross margin averaged 82.05%. At present, Halozyme Therapeutics's current gross margin is 82.4%, which is 0.4 percentage points above its three-year average. During this period, gross margin reached a high of 84.5% in Sep 2025 and a low of 76.8% in Dec 2023.
HALO Operating margin
Halozyme Therapeutics recorded an average operating margin of 46.46% across the last 3 years. Against its three-year average, Halozyme Therapeutics's operating margin is currently 35.9%, 10.6 percentage points below its three-year average. Looking back over the last 3 years, Halozyme Therapeutics's operating margin reached 59.3% at its highest point in Sep 2025 and 33.6% at its lowest in Dec 2025.
HALO EBITDA margin
In the last 3 years, Halozyme Therapeutics had an average EBITDA margin of 56.65%. At present, Halozyme Therapeutics's current EBITDA margin is 43.2%, which is 13.5 percentage points below its three-year average. Looking back over the last 3 years, Halozyme Therapeutics's EBITDA margin reached 68% at its highest point in Sep 2025 and 41% at its lowest in Dec 2025.
HALO Net margin
Looking back over the last 3 years, Halozyme Therapeutics recorded an average net margin of 36.85%. Halozyme Therapeutics's current net margin is 24.9% and is 12 percentage points below its three-year average. The highest net margin for Halozyme Therapeutics was 47.9% in Sep 2025, while the lowest was 22.7% in Dec 2025.
HALO margin group comparison
With a gross margin of 82.4%, HALO is above the Healthcare sector and its peers average but below the industry average. Compared to its Healthcare sector average of 68.3%, Halozyme Therapeutics's gross margin is 21% higher.
HALO margin peer comparison
Frequently asked questions
What is Halozyme Therapeutics's gross margin?
The current gross margin for HALO is 82.4% as of Jun 30, 2026.
What is Halozyme Therapeutics's operating margin?
For the period ending Jun 30, 2026, HALO recorded an operating margin of 35.9%.
What is Halozyme Therapeutics's EBITDA margin?
For the period ending Jun 30, 2026, HALO recorded an EBITDA margin of 43.2%.
What is Halozyme Therapeutics's net margin?
As of Jun 30, 2026, HALO has a net margin of 24.9%.
What are the average margins of HALO?
Across the last 3 years, HALO averaged 82.1% gross, 46.5% operating, 56.7% EBITDA, and 36.9% net.
What are the highest historical margins of HALO?
Over the last 5 years, Halozyme Therapeutics's highest margins were 84.5% gross in Sep 2025, 63.8% operating in Mar 2022, 68% EBITDA in Sep 2025, and 92.2% net in Mar 2022.
What are the lowest historical margins of HALO?
Looking back across 5 years, HALO reached its lowest margins at 76.7% gross in Sep 2023, 33.6% operating in Dec 2025, 41% EBITDA in Dec 2025, and 22.7% net in Dec 2025.